| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| Other Sizes |
| Targets |
Fusidic acid sodium salt targets bacterial protein synthesis by inhibiting the release of translation elongation factor G (EF-G) from ribosomes. By preventing the displacement of mRNA, it blocks protein synthesis, leading to bactericidal effects. It is active against the Gram-positive bacteria S. aureus, S. pyogenes, C. diphtheriae, and B. subtilis.
|
|---|---|
| ln Vitro |
In vitro, Fusidic acid sodium salt exhibits potent antibacterial activity against Gram-positive bacteria, including Staphylococcus aureus and methicillin-resistant strains (MRSA). It inhibits bacterial protein synthesis by preventing the release of EF-G from ribosomes. Its MIC values vary depending on the bacterial strain, with potent activity against staphylococci regardless of methicillin resistance.
|
| ln Vivo |
In vivo, Fusidic acid sodium salt is an orally available antibacterial agent used primarily for treating bacterial infections caused by Staphylococcus aureus. It is often used topically in dermatological treatments for skin infections. It is well absorbed orally and has good tissue penetration. Its bactericidal effect is achieved by inhibiting bacterial protein synthesis.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing for Fusidic acid sodium salt is conducted using broth microdilution or agar dilution methods following CLSI guidelines. Bacterial strains (e.g., S. aureus, S. pyogenes) are cultured in appropriate media and incubated with serial dilutions of the compound. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth.
|
| Cell Assay |
Fusidic acid sodium salt is not typically used in mammalian cell-based assays, as it targets bacterial ribosomes. Cytotoxicity assays may be conducted in mammalian cell lines to assess potential toxicity.
|
| Animal Protocol |
In vivo animal studies for Fusidic acid sodium salt are conducted in rodent models of bacterial infection, particularly those caused by S. aureus. The compound is administered orally or topically. Endpoints include survival, bacterial load in tissues, and histopathological evaluation of infected organs.
|
| ADME/Pharmacokinetics |
Fusidic acid sodium salt is well absorbed following oral administration. It has a molecular weight of 538.69 and a molecular formula of C₃₁H₄₇NaO₆. It is distributed to various tissues, including skin and soft tissues. It is metabolized in the liver and excreted primarily in the bile. Its half-life is approximately 5-10 hours.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Fusidic acid has not yet received marketing approval from the U.S. Food and Drug Administration (FDA), but topical and systemic formulations are available in other countries. Data on fusidic acid excretion in breast milk is outdated and not from rigorously designed studies, but the concentration of the drug in breast milk appears to be low after intravenous fusidic acid administration. When using topical products, ensure that the infant's skin does not come into direct contact with the treated area. Water-soluble creams or gels should only be applied to the breasts, as ointments may expose the infant to high concentrations of mineral oil through licking. Topical application of fusidic acid appears to be relatively ineffective for treating nipple pain and cracking. ◉ Effects on Breastfed Infants As of the revision date, no published information was found. ◉ Effects on Lactation and Breast Milk A small, randomized, non-blinded trial of mothers with nipple pain and cracking showed that applying fusidic acid ointment to the nipples after each breastfeeding session was far less effective than oral antibiotics (cloxacillin or erythromycin, for a 10-day course) (36% vs 79%). Furthermore, 43% of patients did not experience symptom improvement after using fusidic acid, compared to only 16% in the oral antibiotic group; 21% of patients experienced a worsening of their condition after using fusidic acid, compared to only 5% in the oral antibiotic group. Fusidic acid sodium salt is generally well-tolerated. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Liver function abnormalities may occur with prolonged use. It is contraindicated in patients with hypersensitivity to fusidic acid. |
| References |
|
| Additional Infomation |
Fusidate Sodium is the sodium salt of fusidic acid, an antibacterial antibiotic extracted from the fungus Fusidium coccineum, used as a topical medication for treating skin infections. It is an antibiotic isolated from the fermentation broth of Fusidium. (From Merck Index, 11th edition). Its mechanism of action is to inhibit translocation during protein synthesis. See also: Fusidic acid (with active moiety).
Fusidic acid sodium salt is an orally available steroidal antibiotic that inhibits bacterial protein synthesis by preventing EF-G release from ribosomes. It is active against Gram-positive bacteria including MRSA. It has a molecular weight of 538.69 and formula C₃₁H₄₇NaO₆. It is an approved antibiotic. |
| Molecular Formula |
C31H47NAO6
|
|---|---|
| Molecular Weight |
538.69
|
| Exact Mass |
538.327
|
| Elemental Analysis |
C, 69.12; H, 8.79; Na, 4.27; O, 17.82
|
| CAS # |
751-94-0
|
| Related CAS # |
Fusidic acid;6990-06-3
|
| PubChem CID |
23672955
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
635.6ºC at 760 mmHg
|
| Flash Point |
197.6ºC
|
| LogP |
4.331
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1000
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
[Na+].O([H])[C@]1([H])C([H])([H])[C@@]2([H])/C(=C(/C(=O)[O-])\C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])/[C@]([H])(C([H])([H])[C@]2(C([H])([H])[H])[C@@]2(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]3([H])[C@]([H])(C([H])([H])[H])[C@@]([H])(C([H])([H])C([H])([H])[C@]3(C([H])([H])[H])[C@@]21[H])O[H])OC(C([H])([H])[H])=O
|
| InChi Key |
HJHVQCXHVMGZNC-JCJNLNMISA-M
|
| InChi Code |
InChI=1S/C31H48O6.Na/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);/q;+1/p-1/b26-20-;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;/m0./s1
|
| Chemical Name |
sodium (Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoate
|
| Synonyms |
Fusidate Sodium; CEM102; CEM 102; CEM-102
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~185.64 mM)
DMSO : ≥ 100 mg/mL (~185.64 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (185.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8564 mL | 9.2818 mL | 18.5636 mL | |
| 5 mM | 0.3713 mL | 1.8564 mL | 3.7127 mL | |
| 10 mM | 0.1856 mL | 0.9282 mL | 1.8564 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
